|
WUMC Cancer and Leukemia Group B
|
5U10CA077440-13
|
$360,039
|
$3,600
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
|
Wnt antagonist genes in kidney tumor progression and metastasis
|
5R01CA130860-03
|
$625,454
|
$625,454
|
DAHIYA, RAJVIR
|
NORTHERN CALIFORNIA INSTITUTE RES & EDUC
|
|
Vitamin D Pooling Project
|
ZIA CP010195 10436
|
$337,546
|
$57,383
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Virus Hunting
|
ZIA CP005782 10058
|
$12,198
|
$3,050
|
Goedert, James
|
DCEG (NCI)
|
|
VHL Ubiquitin Ligase Activity and Oxygen regulated gene expression
|
5R01CA125930-04
|
$225,720
|
$225,720
|
GNARRA, JAMES
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
VHL
|
ZIA CP005803 08290
|
$216,113
|
$86,445
|
Tucker, Margaret
|
DCEG (NCI)
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
ZIA CP010126 00580
|
$85,856
|
$8,586
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-37S1
|
$101,020
|
$1,010
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-37S2
|
$148,912
|
$1,489
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-37
|
$4,795,480
|
$47,955
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UT M.D. Anderson Cancer Center
|
5U10CA045809-22
|
$2,399,682
|
$23,997
|
FISCH, MICHAEL
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Urologic Oncology Research Training Grant
|
2T32CA082088-11
|
$182,778
|
$18,278
|
SCARDINO, PETER
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Urologic Oncology Branch Consult Core
|
ZID BC 011092
|
$1,953,056
|
$1,171,834
|
Linehan, W. Marston
|
CCR (NCI)
|
|
University of Colorado Southwest Oncology Group
|
2U10CA042777-23
|
$231,603
|
$2,316
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$272,277
|
$54,455
|
Fowler, Daniel
|
CCR (NCI)
|
|
U10 Full Member Application Affiliated with SWOG
|
2U10CA105409-07
|
$325,685
|
$3,257
|
HERBST, ROY
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$10,002
|
$200
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Tumor Induced Dysregulation of T Cell Immunity
|
5R01CA116255-05
|
$261,383
|
$261,383
|
FINKE, JAMES
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Translational Surgical Pathology
|
ZIE SC 000853
|
$251,707
|
$100,683
|
Merino, Maria
|
CCR (NCI)
|
|
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
|
5R01CA109446-07
|
$268,794
|
$268,794
|
Griffith, Thomas
|
UNIVERSITY OF IOWA
|
|
TOLEDO COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
2U10CA035415-27
|
$787,658
|
$15,753
|
MOWAT, REX
|
TOLEDO COMMUNITY HOSPITAL ONCOLOGY PROG
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
1U10CA142559-01
|
$188,304
|
$1,883
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
Tissue Processing/Sequencing Core
|
ZIC BC 011044
|
$552,953
|
$276,477
|
Vocke, Cathy
|
CCR (NCI)
|
|
Tissue Array Research Program
|
ZIC BC 010923
|
$456,762
|
$45,676
|
Hewitt, Stephen
|
CCR (NCI)
|
|
The role of the Ras effector Nore1a in tumor suppression
|
1R01CA133171-01A2
|
$278,258
|
$139,129
|
Clark, Geoffrey
|
UNIVERSITY OF LOUISVILLE
|
|
The Role of Fgf Signaling in Vertebrate Development
|
ZIA BC 010338
|
$316,306
|
$63,261
|
Lewandoski, Mark
|
CCR (NCI)
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-17S1
|
$75,066
|
$751
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-17S2
|
$100,000
|
$1,000
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-17
|
$5,047,305
|
$50,473
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The pVHL/Jade-1/beta-catenin axis in renal cancer
|
2R01CA079830-09A1
|
$330,099
|
$330,099
|
COHEN, HERBERT
|
BOSTON MEDICAL CENTER
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S4
|
$3,823,791
|
$38,238
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S5
|
$100,000
|
$1,000
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S6
|
$50,000
|
$500
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S7
|
$80,000
|
$800
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S8
|
$200,000
|
$2,000
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Gulf Coast MBCCOP
|
5U10CA128536-04
|
$499,869
|
$9,997
|
BEEKER, THADDEUS
|
PROVIDENCE HOSPITAL (MOBILE, AL)
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
2U10CA114671-04
|
$534,190
|
$16,026
|
SOLOMON, WILLIAM
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-04S1
|
$99,947
|
$2,998
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The Brooklyn Minority-Based Community Clinical Oncology Program
|
3U10CA114671-04S2
|
$147,852
|
$4,436
|
Solomon, William
|
SUNY DOWNSTATE MEDICAL CENTER
|
|
The 50th Annual Meeting of the American Society of Pharmacognosy
|
5R13CA139768-02
|
$2,500
|
$750
|
BAKER, BILL
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Telomeres, telomerase and chemotherapy: Bench to bedside
|
5R01CA077091-07
|
$352,225
|
$70,445
|
Au, Jessie
|
OPTIMUM THERAPEUTICS, LLC
|
|
Technical Development of Molecular Profiling Technologies
|
ZIC BC 011041
|
$306,364
|
$153,182
|
Edelman, Daniel
|
CCR (NCI)
|
|
Targeting Tumor Angiogenesis with G-Quadruplex Binders
|
3R01CA109069-05S2
|
$54,629
|
$27,315
|
SUN, DAEKYU
|
UNIVERSITY OF ARIZONA
|
|
Targeting Tumor Angiogenesis with G-Quadruplex Binders
|
5R01CA109069-05
|
$260,253
|
$130,127
|
SUN, DAEKYU
|
UNIVERSITY OF ARIZONA
|
|
Targeting the PI3-Kinase/Akt Pathway for the Therapy of Renal Cell Carcinoma
|
5K08CA142890-02
|
$169,400
|
$169,400
|
Cho, Daniel
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting Novel T Cell Antigens on Renal Cell Carcinoma
|
5K08CA121912-05
|
$134,460
|
$134,460
|
TYKODI, SCOTT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeting HIF-1alpha in renal cell carcinoma: the role of HDAC inhibitors
|
5R01CA135321-03
|
$341,073
|
$341,073
|
Pili, Roberto
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Tailored Algorithms for Non-Contrast Computed Tomography Using Sinogram Restorati
|
5R01CA134680-03
|
|
$0
|
LA RIVIERE, PATRICK
|
UNIVERSITY OF CHICAGO
|
|
Symptom Cluster Subgroups in Adult Survivors of Childhood Cancers
|
5R01CA136912-02
|
$239,033
|
$23,903
|
Finnegan, Lorna
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
|
3U24CA114766-05S1
|
$1,195,618
|
$239,124
|
Ramirez, Nilsa
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
Total relevant funding to Kidney Cancer for this search: $44,578,835
|